We do not support your browser. Please take a moment and upgrade to the most recent version of Internet Explorer.

NIH/NCATS Drug Development Collaboratory: Therapeutic Development Branch & Extramural Researchers
Deadline: January 09, 2021 02:00 PM

Save this event to your calendar.  Download to Outlook Download to iCal

The purpose of the PAR-20-301 Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations on late-stage translational science projects between NCATS Therapeutic Development Branch (TDB) and extramural researchers, for therapeutic development of small molecules, biologics, or gene therapies. The UG3 phase will provide support for late stage pre-clinical work and clinical trial planning that is conducted at applicant institutions.

The goal of any collaboration with TDB is to enable an IND application by the end of the UG3 phase. If UG3 milestones are met and an IND is cleared, support may be provided for an early stage clinical trials in the UH3 phase that will be conducted at the applicant institutions.

Earliest Submission Deadline: Letter of Intent due Jan. 9, 2021

Full details here.

Return to Deadline Listings